aducanumab Archives -

Biogen and partner Eisai have said they will run a large-scale observational study of Alzheimer’s drug Aduhelm in

Biogen adds real-world test for Aduhelm to its confirmatory trial

https://pharmaphorum.com/news/biogen-adds-real-world-test-for-aduhelm-to-its-confirmatory-trial/

FDA staffers defend Aduhelm approval in JAMA editorial

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, Eisai, fda, neurology, regulatory 0 Comment

Three FDA figures at the centre of the fallout over the approval Biogen and Eisai’s Alzheimer’s disease therapy

FDA staffers defend Aduhelm approval in JAMA editorial

https://pharmaphorum.com/news/fda-staffers-defend-aduhelm-approval-in-jama-editorial/

News/ News/ Sales and Marketing

Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, Biogen, Drug pricing, Eisai, neurology 0 Comment

Biogen has hinted that it may consider altering the price of its controversially-approved Alzheimer’s therapy Aduhelm – but

Amid outcry over Aduhelm price, Biogen says it may consider ‘adjustment’

https://pharmaphorum.com/news/amid-outcry-over-aduhelm-price-biogen-says-it-may-consider-adjustment/

Market Access/ News/ News

Consumer group seeks resignation of top FDA staffers over Aduhelm okay

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, fda, Janet Woodcock, neurology, senior management 0 Comment

With the first patient set to receive Biogen’s new Alzheimer’s drug Aduhelm in Rhode Island today, US consumer

Consumer group seeks resignation of top FDA staffers over Aduhelm okay

https://pharmaphorum.com/news/consumer-group-seeks-resignation-of-top-fda-staffers-over-aduhelm-okay/

Market Access/ News/ News

And then there were three: another FDA adcomm member quits over Aduhelm

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, Biogen, central nervous system, fda, neurology 0 Comment

The fallout over the FDA’s decision to approved Biogen’s Alzheimer’s therapy Aduhelm continues to be felt, with a

And then there were three: another FDA adcomm member quits over Aduhelm

https://pharmaphorum.com/news/and-then-there-were-three-another-fda-adcomm-member-quits-over-aduhelm/

Market Access/ News/ News

Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

Phil Taylor aducanumab, Aduhelm, Alzheimer's, amyloid, Biogen, central nervous system, fda, neurology, regulatory 0 Comment

Two members of an FDA advisory committee have now resigned in protest over Monday’s approval of Biogen’s Alzheimer’s

Double resignation over Aduhelm approval depletes FDA’s CNS adcomm

https://pharmaphorum.com/news/double-resignation-over-aduhelm-approval-depletes-fdas-cns-adcomm/

Market Access/ News/ News

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, Biogen, Drug pricing, fda, ICER, neurology 0 Comment

The FDA “has failed in its responsibility to protect patients and families from unproven treatments with known harms”

FDA slammed over Aduhelm OK as Biogen takes heat for $56k price tag

https://pharmaphorum.com/news/fda-slammed-over-aduhelm-ok-as-biogen-takes-heat-for-56k-price-tag/

Market Access/ News/ News

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

Phil Taylor aducanumab, Aduhelm, Alzheimer's disease, amyloid, Biogen, fda, neurology 0 Comment

Biogen and Eisai have defied the naysayers and secured an historic FDA approval for their amyloid-targeting antibody aducanumab

Jubilation for Biogen, Eisai as FDA says ‘yes’ to aducanumab

https://pharmaphorum.com/news/jubilation-at-biogen-as-fda-says-yes-to-aducanumab/

News/ News/ R&D

FDA grew too close to Biogen during Alzheimer’s drug development, doctors say

Richard Staines aducanumab, Alzheimer's, Biogen, Eisia, neurology, R&D 0 Comment

The FDA got too close to Biogen during the development of the Alzheimer’s drug aducanumab, according to its

FDA grew too close to Biogen during Alzheimer’s drug development, doctors say

https://pharmaphorum.com/news/fda-grew-too-close-to-biogen-during-alzheimers-drug-development-doctors-say/

Trending

aducanumab

Login